Public Release: 

Immediate treatment with clot-stabilizing drug could save thousands of lives every year

The Lancet

Study shows that every minute counts when it comes to treating severe bleeding after trauma or childbirth

Time is of the essence when it comes to administering the clot-stabilising drug tranexamic acid to people with serious injury or women with severe bleeding after childbirth, according to a meta-analysis of over 40,000 patients, published in The Lancet. The study found that the likelihood of death due to blood loss was reduced by over 70% if the low-cost, readily-available drug was given immediately after injury or birth. But the chances of survival fell by 10% for each 15 minute delay, with no benefit seen after 3 hours.

"Responding quickly can be the difference between life and death, and that means patients must be treated urgently at the scene of injury or as soon as the diagnosis of haemorrhage is made. We have to make sure tranexamic acid is available before patients reach hospital and whenever a woman gives birth," says Professor Ian Roberts from the London School of Hygiene & Tropical Medicine, UK, who initiated the study. [1]

Every year, more than 2 million people worldwide die from traumatic extracranial bleeding, often as a result of road traffic injuries and violence. Furthermore, post-partum haemorrhage (excessive bleeding after childbirth) is the leading cause of maternal death worldwide, killing around 100,000 women a year.

Antifibrinolytic drugs such as tranexamic acid, aminocaproic acid, and aprotinin work by stopping blood clots from breaking down and reducing bleeding. They have been used for many years to reduce heavy menstrual bleeding and are often given during surgery to reduce the need for blood transfusions.

This new study builds on previous research from the WOMAN and CRASH-2 trials which showed that tranexamic acid cut deaths due to post-partum haemorrhage and bleeding after serious injury by about a third if given within 3 hours of bleeding onset. [2]

In this new analysis, Roberts and colleagues did a meta-analysis of individual patient data from these two trials, involving 40,138 men and women and found that almost two-thirds of bleeding deaths occurred within 12 hours of onset (884 of 1,408 bleeding deaths). Deaths due to post-partum haemorrhage peaked 2-3 hours after childbirth.

Overall, survival from severe bleeding was increased by a fifth with the use of tranexamic acid compared to placebo, irrespective of the site of bleeding (1.5% of women given tranexamic acid died of bleeding [155/10034] vs 1.9% of women given placebo plus standard care [190/9977], and 4.9% trauma patients given tranexamic acid died of bleeding [489/10060] vs 5.7% given placebo and standard care [574/10067]). This figure rose to 70% if the drug was administered immediately. For every 15 minute delay in treatment, survival benefit was cut by about 10%, even after taking into account age and systolic blood pressure, which are strong risk factors for death due to bleeding. No benefit was seen if treatment was delayed beyond 3 hours.

The researchers also found no evidence of complications or increased risk of clotting (i.e., heart attack, stroke, pulmonary embolism, and deep vein thrombosis) compared to placebo, and fewer cases of heart attacks were noted with tranexamic acid.

The authors explain that because treatment delay may be underestimated in trauma (many injuries are unwitnessed), and overestimated in post-partum haemorrhage (birth is taken as the time of bleeding onset), they did sensitivity analyses to test a range of plausible errors. Their results support the conclusion that prompt treatment is essential.

The authors also explain that their systematic review identified a total of 13 trials on tranexamic acid conducted between 1946 and 2017, but the ones included in this meta-analysis were the only two trials to assess the impact of time to treatment on treatment effectiveness.

Professor Roberts explains: "Tranexamic acid is safe, cheap, easily administered, and does not need to be refrigerated. Most haemorrhage deaths occur within hours of bleeding onset. Prompt treatment has the potential to save thousands of additional lives worldwide every year." [1]

"Given the importance of early treatment, time from bleeding onset to early treatment should be audited and communicated to health-care professionals. Establishing national or regional quality improvement initiatives, with best practice benchmarking of time to treatment, might improve survival. More research is needed to improve our understanding of the mechanism of action of this life-saving treatment." [1]

Writing in a linked Comment, Dr David Dries, Chair of the Department of Surgery at HealthPartners Medical Group, Minnesota, and Professor of surgery at the University of Minnesota, USA, welcomes the study: "A multitude of trials can be identified in registries, such as ClinicalTrials.gov from the US National Library of Medicine, reflecting ongoing work with tranexamic acid. At present, the careful study of Gayet-Ageron and coworkers suggests applicability of early administration of this agent in patients with substantial bleeding from multiple causes. As data from additional trials with tranexamic acid become available, the spectrum of applications for this agent should become apparent."

###

NOTES TO EDITORS

The study was funded by UK NIHR Health Technology Assessment programme, Pfizer, BUPA Foundation, and J P Moulton Charitable Foundation (CRASH-2 trial). London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation (WOMAN trial).

[1] Quotes direct from author and cannot be found in text of Article.

[2] Woman trial (The Lancet, 2017) http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30638-4/fulltext; CRASH-2 trial (The Lancet, 2011) http://www.thelancet.com/crash-2

The research findings will be part of the discussion at a special event on postpartum haemorrhage taking place at the London School of Hygiene & Tropical Medicine on 9 November. As part of the event, a unique art installation called the 'Blood Clock' (created by a Consultant Obstetrician) will be unveiled to raise awareness of postpartum haemorrhage and the need for urgent treatment. Details plus livestream: https://www.lshtm.ac.uk/newsevents/events/how-can-we-stop-women-bleeding-death-childbirth-woman-trial-panel-event-and-blood

For interviews with article author Professor Ian Roberts please contact the London School of Hygiene & Tropical Medicine press office E) press@lshtm.ac.uk T) 44-0-207-927-2802

For interviews with comment author Dr David Dries, Chair of the Department of Surgery at HealthPartners Medical Group, Minnesota, USA please contact E) david.j.dries@healthpartners.com T) 1-615-254-1633

For embargoed access to the Article and Comment, please see: http://www.thelancet-press.com/embargo/WOMAN2.pdf For embargoed access to the Appendix, please see: http://www.thelancet-press.com/embargo/WOMAN2APPX.pdf

NOTE: THE ABOVE LINK IS FOR JOURNALISTS ONLY; IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32455-8/fulltext?elsca1=tlpr

Emily Head
Press Officer
The Lancet journals, 125 London Wall, London EC2Y 5AS
T: 44-0-207-424-4249
M: 44-0-7920-530-997
E: emily.head@lancet.com

This email has been sent from The Lancet, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084.

Email us directly to unsubscribe from The Lancet press releases. Privacy Policy

Copyright © 2017 Elsevier Limited except certain content provided by third parties. The Lancet is a trade mark of RELX Intellectual Properties SA, used under license.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.